Cizzle Biotechnology launches its new corporate website

Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, has announce that it has launched its new corporate website, which can be viewed at: https://cizzlebiotechnology.com

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

“I am delighted to announce that our new website is now live for all stakeholders including shareholders, investors and customers, to access a wide range of information and latest news on the Company’s status and products. This is an exciting time for Cizzle Biotechnology as we continue to finalise our near term regulatory and launch plans in the USA as part of our global strategy to bring the non-invasive, cost effective, CIZ1B Biomarker test for early-stage lung cancer to market.  The new website is designed to provide a user-friendly interface for all stakeholders and we look forward to adding new content as part of an enhanced communication strategy to support the Company’s growth.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Cizzle Biotechnology raises £150k to support cancer test rollout

    Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe.

    Cizzle Bio expands into Caribbean with first contract, secures early royalties

    Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout.

    Cizzle Biotechnology launches its new corporate website

    Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy.

    Cizzle Biotechnology appoints Matt Bower as a Non-Executive Director

    Cizzle Biotechnology appoints Matt Bower as Non-Executive Director, enhancing its board for growth as it prepares to launch innovative cancer tests globally.

    Cizzle Bio appoints iGenomeDX to launch CIZ1B biomarker test in USA

    Cizzle Biotechnology announces a breakthrough in early lung cancer detection with iGenomeDX appointed to launch the CIZ1B biomarker test across the USA.

    Cizzle Biotechnology appoints Professor Dawn Coverley as Chief Scientific Officer

    Cizzle Biotechnology names Professor Dawn Coverley as Chief Scientific Officer, marking a strategic shift. She will focus on advancing the CIZ1B biomarker assay.

      Search

      Search